Description
Escitalopram is the S-enantiomer of racemic citalopram; like citalopram, this compound is an SSRI that exhibits antidepressant and anxiolytic qualities and is also effective in treating OCD. Escitalopram inhibits the serotonin transporter (SERT), preventing reuptake of serotonin. Escitalopram may have other potential uses, as it decreased weight in a study of obese subjects with binge eating disorder and displayed anti-inflammatory activity through inhibition of NO and TNF-α production. This compound is associated with prolongation of the cardiac QT interval and may inhibit osteoblast and osteoclast formation as well.
References
Hodge JM, Wang Y, Berk M, et al. Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Biol Psychiatry. 2013 Jul 1;74(1):32-9. PMID: 23260229.
Tynan RJ, Weidenhofer J, Hinwood M, et al. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. 2012 Mar;26(3):469-79. PMID: 22251606.
Zhong H, Haddjeri N, Sánchez C. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action. Psychopharmacology (Berl). 2012 Jan;219(1):1-13. PMID: 21901317.
van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med. 2009 Sep;54(3):404-8. PMID: 19556032.
Stein DJ, Andersen EW, Tonnoir B, et al. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin. 2007 Apr;23(4):701-11. PMID: 17407626.
Kasper S, Stein DJ, Loft H, et al. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry. 2005 Mar;186:222-6. PMID: 15738503.
